Tag: NASDAQ: NVCR

Mesothelioma

NovoCure (NASDAQ:NVCR) Lifted to Overweight at Wells Fargo & Company

November 29, 2022
Lucy G. Lovins

NovoCure (NASDAQ:NVCR – Get Rating) was upgraded to an “overweight” rating by research analysts at Wells…

Mesothelioma

NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Hold” by Brokerages

November 22, 2022
Lucy G. Lovins

NovoCure Limited (NASDAQ:NVCR – Get Rating) shares have received a consensus rating of “Hold” from the…

Mesothelioma

Midday Report: NovoCure (NVCR) Falls on October 24

October 24, 2022
Lucy G. Lovins

Last price $ last trade change $ change percent % Open $ Back Close $ High…

Mesothelioma

NovoCure (NASDAQ:NVCR) Rating Lowered to Neutral at Piper Sandler

October 24, 2022
Lucy G. Lovins

NovoCure (NASDAQ:NVCR – Get Rating) was downgraded from an “overweight” rating to a “neutral” rating by…

Mesothelioma

NovoCure (NVCR) to Release Earnings on Thursday

October 20, 2022
Lucy G. Lovins

NovoCure (NASDAQ:NVCR – Get Rating) is expected to release its quarterly results before the market opens…

Mesothelioma

NovoCure Limited (NASDAQ:NVCR) Insider Sells $513,371.54 in Stock

October 17, 2022
Lucy G. Lovins

NovoCure Limited (NASDAQ:NVCR – Get Rating) insider Frank X. Leonard sold 6,754 shares of the company’s…

Mesothelioma

Frank X. Leonard Sells 6,754 Shares of NovoCure Limited (NASDAQ:NVCR) Stock

October 7, 2022
Lucy G. Lovins

NovoCure Limited (NASDAQ:NVCR – Get Rating) insider Frank X. Leonard sold 6,754 shares of NovoCure in…